Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 130
Filtrar
1.
Actas Dermosifiliogr ; 2024 Feb 22.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-38395225

RESUMO

BACKGROUND: Alopecia areata (AA) is an autoimmune disease characterized by non-scaring hair loss and preservation of hair follicles. The information available on disease course, and clinical features of AA is scarce worldwide, and almost nonexistent in Colombia. OBJECTIVE: To determine the clinical and sociodemographic characteristics of patients diagnosed with AA who presented to a dermatology consultation in five Colombian cities. MATERIAL AND METHODS: This was a retrospective and multicenter study on data from an ongoing National Registry of Alopecia Areata in Colombia (RENAAC) collected in Bogota, Cali, Cartagena, Barranquilla, and Medellin, Colombia from March 2022 through April 2023. Data was recorded in a standardized form by trained physicians. The variables were expressed as measures of central tendency and dispersion, and absolute and relative frequencies. RESULTS: A total of 562 patients were included, 59.4% of whom were women, aged between 15 and 49 years (63.9%) with a mean disease course of 1.7 years. The most common finding was multiple plaque (53.2%), the predominant AA subtype was patchy (71.4%), and 29.5% of the patients had a past dermatological history, 18.3% had a past endocrinological history, and 8.9% had a past psychiatric history. The treatments most widely used were steroid injections (76.4%), 5% topical minoxidil (46.4%), followed by high-potency corticosteroids (42.5%). STUDY LIMITATIONS AND CONCLUSIONS: AA was slightly predominant in women. As seen in other populations, this disease had an earlier onset in men vs women. Presentation in pediatric age was uncommon. The previous history of other dermatological diseases was checked in almost one third of the patients. Analysis of the co-presentation of AA with other autoimmune diseases is biased due to excluding patients with systemic erythematous lupus from the study.

2.
Rev Esp Quimioter ; 33(6): 430-435, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33246358

RESUMO

OBJECTIVE: Methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum ß-lactamase-producing Enterobacterales (ESBL-E) may complicate the treatment of diabetic foot infections (DFIs). The aim of this study was to determine the risk factors for these pathogens in DFIs. METHODS: This was a prospective observational study of 167 consecutive adult patients with DFIs. The diagnosis and severity of DFIs were based on the Infectious Disease Society of America (IDSA) classification system. Multivariate analyses were performed in order to identify risk factors for MRSA and ESBL-E infections. RESULTS: S. aureus was the most isolated pathogen (n=82, 37.9 %) followed by Escherichia coli (n= 40, 18.5%). MRSA accounted for 57.3% of all S. aureus and 70% of Klebsiella pneumoniae and 25% of E. coli were ESBL producers, respectively. Deep ulcer [OR 8,563; 95% CI (1,068-4,727)], previous use of fluoroquinolones [OR 2,78; 95% CI (1,156-6,685)] and peripheral vasculopathy [OR 2,47; 95% CI (1.068-4.727)] were the independent predictors for MRSA infections; and osteomyelitis [OR 6,351; 95% CI (1,609-25,068)] and previous use of cephalosporins [OR 5,824; 95% CI (1,517-22,361)] for ESBL-E infections. CONCLUSIONS: MRSA and ESBL-E have adquired a great clinical relevance in DFIs. The availability of their risk factors is very convenient to choose the empirical treatment in severe forms.


Assuntos
Diabetes Mellitus , Pé Diabético , Staphylococcus aureus Resistente à Meticilina , Adulto , Pé Diabético/microbiologia , Escherichia coli , Hospitais , Humanos , Fatores de Risco , beta-Lactamases
3.
An. pediatr. (2003. Ed. impr.) ; 83(3): 183-190, sept. 2015. tab
Artigo em Espanhol | IBECS | ID: ibc-143712

RESUMO

INTRODUCCIÓN Y OBJETIVOS: Streptococcus pneumoniae (SP) es un patógeno que causa un elevado consumo de antibióticos. OBJETIVOS: conocer la sensibilidad a antibióticos de uso habitual, los factores epidemiológicos asociados y favorecer el uso racional de antibióticos. PACIENTES Y MÉTODOS: En verano del 2009 y el invierno del 2010 realizamos un estudio multicéntrico en Atención Primaria (AP). Se recogió una muestra nasofaríngea y se cumplimentó una encuesta epidemiológica en 1.562 niños de 1 y 4 años. RESULTADOS: El 31,3% (489/1.562) eran portadores nasales (PN). Se realizó un estudio de sensibilidad en 376 aislados, y se serotipificaron 343. El 61,7% (964/1.562) habían recibido al menos una dosis de vacuna antineumocócica conjugada heptavalente (PCV7). El 12,8% (44/343) correspondía a serotipos vacunales (SV). La resistencia a penicilina (criterio meningitis CMI>0,06mg/l) fue del 28%, siendo del 54% para los SV. Para infecciones no meníngeas, el 100% de los aislados eran sensibles a penicilina parenteral (CMI ≤ 2mg/l). Existe un alto nivel de resistencias para eritromicina (45,8%). Fueron factores favorecedores de resistencia haber tomado antibióticos el mes previo y ser portador de SV tanto para penicilina como para cefotaxima y la edad de 4 años un factor de protección. Los serotipos 14, 35B, 19A, 15A y 19F fueron los menos susceptibles a penicilina. CONCLUSIONES: La amoxicilina por vía oral para pacientes ambulatorios y la penicilina o ampicilina por vía intravenosa para pacientes ingresados son excelentes opciones para el tratamiento de infecciones neumocócicas no meníngeas, en entornos como el nuestro, con una baja incidencia de aislados con alto nivel de resistencia a penicilina (CMI ≥ 2mg/l)


INTRODUCTION AND OBJECTIVES: Streptococcus pneumoniae (SP) is a human pathogen that involves a high use of antibiotics. The objective of the study was to determine the susceptibility to commonly used antibiotics and their associated risk factors, in order to promote rational use of antibiotics. PATIENTS AND METHODS: In A multicentre study was conducted in summer 2009 and winter 2010 on children attending paediatric clinics in the Region of Murcia. A nasopharyngeal sample was collected and an epidemiological questionnaire was completed. The study included 1562 children aged 1 and 4 years old. RESULTS: Almost one-third (31.3%, 489/1562) of children were nasal carriers. A sensitivity study was carried out on 376 isolates, of which 343 were serotyped. Almost two-thirds (61.7%, 964/1562) of children had received at least one dose of PCV7 heptavalent pneumococcal conjugate vaccine), and 12.8% (44/343) of the isolates belonged to PCV7 serotypes. The prevalence rates of penicillin resistance (meningitis infections criteria CMI>0.06mg/L) were 28.1%; however, this percentage was 54% in PCV7 serotypes. None of the isolates had (MIC >2mg/L), so prevalence rates of susceptibility with non-meningitis infections criteria were 100%. There was a high percentage of erythromycin resistance (45.7%). The factors favouring resistance to penicillin and cefotaxime were the consumption of antibiotics in the previous month and the carrying of vaccine serotypes. On the other hand, the age of 4 years old was a protective factor of resistance. The 14, 35B, 19A, 15A, and 19F serotypes were less susceptible to penicillin. CONCLUSIONS: Both oral amoxicillin given to outpatients and intravenous penicillin or ampicillin to hospitalized patients are excellent options for the treatment of non-meningeal infections, as seen with pneumonia in these kinds of environments, where there is low incidence of isolates highly resistant to penicillin (CMI ≥ 2mg/L)


Assuntos
Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Streptococcus pneumoniae/patogenicidade , Streptococcus pneumoniae/isolamento & purificação , Resistência às Penicilinas , Cefotaxima/farmacologia , Eritromicina/farmacologia , Infecções Pneumocócicas/tratamento farmacológico , Infecções Pneumocócicas/etiologia , Ampicilina/uso terapêutico , Penicilinas/uso terapêutico , Monitoramento Epidemiológico/tendências , Nasofaringe/microbiologia , Resistência a Medicamentos , Vacinas Pneumocócicas/administração & dosagem , Vacinas Conjugadas/administração & dosagem , Sorotipagem , Comercialização de Medicamentos , Portador Sadio , Atenção Primária à Saúde , Estudos Transversais , Espanha/epidemiologia
4.
An Pediatr (Barc) ; 83(3): 183-90, 2015 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-25453309

RESUMO

INTRODUCTION AND OBJECTIVES: Streptococcus pneumoniae (SP) is a human pathogen that involves a high use of antibiotics. The objective of the study was to determine the susceptibility to commonly used antibiotics and their associated risk factors, in order to promote rational use of antibiotics. PATIENTS AND METHODS: In A multicentre study was conducted in summer 2009 and winter 2010 on children attending paediatric clinics in the Region of Murcia. A nasopharyngeal sample was collected and an epidemiological questionnaire was completed. The study included 1562 children aged 1 and 4 years old. RESULTS: Almost one-third (31.3%, 489/1562) of children were nasal carriers. A sensitivity study was carried out on 376 isolates, of which 343 were serotyped. Almost two-thirds (61.7%, 964/1562) of children had received at least one dose of PCV7 (heptavalent pneumococcal conjugate vaccine), and 12.8% (44/343) of the isolates belonged to PCV7 serotypes. The prevalence rates of penicillin resistance (meningitis infections criteria CMI>0.06mg/L) were 28.1%; however, this percentage was 54% in PCV7 serotypes. None of the isolates had (MIC >2mg/L), so prevalence rates of susceptibility with non-meningitis infections criteria were 100%. There was a high percentage of erythromycin resistance (45.7%). The factors favouring resistance to penicillin and cefotaxime were the consumption of antibiotics in the previous month and the carrying of vaccine serotypes. On the other hand, the age of 4 years old was a protective factor of resistance. The 14, 35B, 19A, 15A, and 19F serotypes were less susceptible to penicillin. CONCLUSIONS: Both oral amoxicillin given to outpatients and intravenous penicillin or ampicillin to hospitalized patients are excellent options for the treatment of non-meningeal infections, as seen with pneumonia in these kinds of environments, where there is low incidence of isolates highly resistant to penicillin (CMI ≥ 2mg/L).


Assuntos
Antibacterianos/farmacologia , Streptococcus pneumoniae/efeitos dos fármacos , Portador Sadio , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Lactente , Masculino , Testes de Sensibilidade Microbiana , Nariz/microbiologia , Faringe/microbiologia , Infecções Pneumocócicas , Prevalência , Sorogrupo , Espanha , Streptococcus pneumoniae/classificação , Streptococcus pneumoniae/isolamento & purificação
5.
Rev. esp. quimioter ; 21(2): 115-122, jun. 2008. tab
Artigo em Espanhol | IBECS | ID: ibc-77580

RESUMO

actualidaduno de los problemas más importantes de la patologíainfecciosa. La relación entre resistencia bacteriana in vitro yrespuesta clínica in vivo no siempre está bien definida, yaque el fallo terapéutico puede estar determinado por otrosfactores (farmacocinéticos y farmacodinámicos). Ademáshay discordancias entre la actividad in vitro e in vivo de diversosantimicrobianos (sobre todo el ciprofloxacino) debidoa su baja actividad bactericida. En infecciones por S. pyogenes,S. aureus, S. epidermidis, E. faecalis, E. coli productorde betalactamasas de espectro extendido (BLEE), K. pneumoniaey E. cloacae sensibles al ciprofloxacino su uso clínicono se asocia con curación por el desarrollo de resistenciasinducibles durante el tratamiento antibiótico. De igual forma,la ceftazidima en infecciones por K. pneumoniae y E. cloacaesensibles a esta cefalosporina y ceftriaxona en infeccionespor S. aureus sensibles a la meticilina no tienen buenacorrelación clínico-microbiológica por su baja actividad bactericiday el desarrollo de resistencias durante el tratamiento.El principal impacto clínico de las resistencias bacterianases que muchos tratamientos empíricos son inadecuadosy esto se traduce en un aumento de la mortalidad, especialmenteen las infecciones graves con bacteriemia porS. aureus resistente a la meticilina, enterobacterias productorasde BLEE, P. aeruginosa y A. baumannii multirresistentes.Uno de los principales factores de riesgo para el desarrollode resistencias bacterianas es el incremento del consumode diversos grupos de antibióticos. Los programas deprotocolización consensuada del tratamiento antibióticopueden disminuir el desarrollo de resistencias bacterianas. Elconocimiento del uso previo de antibióticos es un elementode especial relevancia en la sospecha clínica precoz de infecciónbacteriana resistente (AU)


Bacterial resistance is currently one of the most importantproblems of infectious pathology. The relationbetween in vitro and in vivo bacterial resistance is notalways well defined because therapeutic failure is alsorelated to other factors (pharmacokinetics and pharmacodynamics).In addition, there are disagreements betweenthe in vitro and in vivo activity of several antimicrobials(especially ciprofloxacin) due to their lowbactericidal activity. In infections due to ciprofloxacinsusceptible S. pyogenes, S. aureus, S. epidermidis, E. faecalis,E. coli producing extended spectrum beta-lactamase(ESBL), K. pneumoniae and E. cloacae their clinicaluse is not associated to cure because of the developmentof resistances that are induced during the antibiotictreatment. Ceftazidime in infections due to susceptiblestrains of K. pneumoniae and E. cloacae and ceftriaxonein infections due to methicillin susceptible S. aureus alsodo not have a good correlation between in vitro and invivo results due to their low bactericidal activity and tothe development of resistances during treatment.The main clinical impact of resistant bacteria is relatedto the failure of empirical treatments, which is associatedto a higher mortality, especially in severe infections with methicillin-resistant S. aureus, Enterobacteriae ESBLand multiresistant P. aeruginosa and A. baumannii.One of the main risk factors for the development ofbacterial resistances is the increase of the consumptionof several antibiotics. The development of protocolsagreed upon by consensus may decrease the impact ofbacterial resistances (AU)


Assuntos
Humanos , Masculino , Feminino , Doenças Transmissíveis/classificação , Doenças Transmissíveis/complicações , Doenças Transmissíveis/imunologia , Doenças Transmissíveis/terapia , Antibacterianos/administração & dosagem , Antibacterianos/síntese química , Antibacterianos , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Doença Pulmonar Obstrutiva Crônica/complicações , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/terapia
6.
Rev Esp Quimioter ; 21(2): 115-22, 2008 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-18509770

RESUMO

Bacterial resistance is currently one of the most important problems of infectious pathology. The relation between in vitro and in vivo bacterial resistance is not always well defined because therapeutic failure is also related to other factors (pharmacokinetics and pharmacodynamics). In addition, there are disagreements between the in vitro and in vivo activity of several antimicrobials (especially ciprofloxacin) due to their low bactericidal activity. In infections due to ciprofloxacin susceptible S. pyogenes, S. aureus, S. epidermidis, E. faecalis, E. coli producing extended spectrum beta-lactamase (ESBL), K. pneumoniae and E. cloacae their clinical use is not associated to cure because of the development of resistances that are induced during the antibiotic treatment. Ceftazidime in infections due to susceptible strains of K. pneumoniae and E. cloacae and ceftriaxone in infections due to methicillin susceptible S. aureus also do not have a good correlation between in vitro and in vivo results due to their low bactericidal activity and to the development of resistances during treatment. The main clinical impact of resistant bacteria is related to the failure of empirical treatments, which is associated to a higher mortality, especially in severe infections with methicillin-resistant S. aureus, Enterobacteriae ESBL and multiresistant P. aeruginosa and A. baumannii. One of the main risk factors for the development of bacterial resistances is the increase of the consumption of several antibiotics. The development of protocols agreed upon by consensus may decrease the impact of bacterial resistances. The knowledge of the previous use of antibiotics is an especially relevant issue to suspect that an infection might be due to resistant bacteria. Resistant pathogens are a severe problem in the clinical setting and the question is of such a complexity that it requires a multidisciplinary effort that involves the different professionals of the Internal Medicine-Infectious Diseases, Microbiology, Pharmacology, Pharmacy and Preventive Medicine Departments and hospital directors and that results in unified and protocolized actions regarding the clinical and therapeutical approach for the management of severely infected patients.


Assuntos
Farmacorresistência Bacteriana , História do Século XX , Humanos , Fatores de Risco
8.
Rev Esp Quimioter ; 19(3): 258-66, 2006 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-17099794

RESUMO

The incidence of multidrug-resistant Enterococcus faecium is increasing despite advances in antibacterial therapy. Thus, new antibiotics are required to treat hospital- or community-acquired infections caused by these multidrug-resistant organisms. The aim of this study was to compare the therapeutic efficacy of quinupristin-dalfopristin (QD) alone, or in combination with gentamicin (G), teicoplanin (T), imipenem (I) or levofloxacin (L) against a strain of multidrug-resistant E. faecium in an experimental model of aortic valve endocarditis in rabbits. The study group consisted of 28 control animals. Eighty-two animals were treated with one of the following antibiotic regimens: G1: 18 animals QD (30 mg/kg/8 h); G2: 18 animals QD+G (6 mg/kg/12 h); G3: 16 animals QD+T (20 mg/kg/12 h); G4: 14 animals QD+I (60 mg/kg/8 h); and G5: 16 animals QD+L (20 mg/kg/12 h). The response to therapy was determined by the comparison of the number of CFU/g of E. faecium in each vegetation. In vitro, time-kill studies looking for synergy for the combinations that showed better efficacy in vivo were done. The sensitivity of the strain was intermediate to QD, resistant to T and I, and sensitive to L. There was no high-level resistance to G. QD alone revealed a significant decrease (p <0.001) in the CFU/g in the control group (9.49 vs. 7.31). There were no differences in the average of CFU/g between the QD alone (G1), QD+G (G2) and QD+T (G3) groups. These three groups revealed a significant difference in decrease of CFU/g respect of the group control (p <0.001). There were no differences in the average of CFU/g between QD+I (G4) and QD+T (G5). These two groups revealed the greatest decrease in average CFU/g (G4: 4.38 and G5: 4.04) with differences respect of the group control (p <0.0001) and respect of the groups G1, G2 and G3 (p <0.001). We did not detect any alteration of MIC from QD in the course of the treatment for either of the final isolations. Only the time kill corresponding to concentrations of I 32 mg/l (0.25 x MIC) and QD 1 mg/l (0.25 x MIC presents a descending slope in the curve at 4 and 8 h, suggesting an early synergy phenomenon, which was lost after 8 h. In light of these results, the combination QD with I and L may be considered suitable alternatives for the treatment of multiresistant E. faecium.


Assuntos
Antibacterianos/uso terapêutico , Endocardite Bacteriana/tratamento farmacológico , Enterococcus faecium/efeitos dos fármacos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Virginiamicina/uso terapêutico , Idoso , Animais , Modelos Animais de Doenças , Farmacorresistência Bacteriana Múltipla , Quimioterapia Combinada , Endocardite Bacteriana/microbiologia , Enterococcus faecium/isolamento & purificação , Feminino , Gentamicinas/uso terapêutico , Infecções por Bactérias Gram-Positivas/microbiologia , Humanos , Imipenem/uso terapêutico , Levofloxacino , Testes de Sensibilidade Microbiana , Ofloxacino/uso terapêutico , Coelhos , Teicoplanina/uso terapêutico
10.
Rev. esp. quimioter ; 19(3): 258-266, sept. 2006. tab, graf
Artigo em Es | IBECS | ID: ibc-050284

RESUMO

La incidencia de infecciones por Enterococcus faecium multirresistentes va aumentando a pesar de los avances que se han producido en antibioticoterapia.Por ello, se necesitan nuevos antibióticos para tratar las infecciones nosocomiales o comunitarias causadas por este microorganismo.El objetivo principal del presente estudio fue comparar la eficacia de quinupristina-dalfopristina (QD), sola o combinada con gentamicina(G), teicoplanina (T), imipenem (I) o levofloxacino (L), en un modelo de endocarditis experimental en conejos por E. faecium multirresistente.Se utilizaron 110 animales, 28 como grupo control y 82 como grupos terapéuticos, que fueron G1: 18 animales con QD (30mg/kg/8 h); G2: 18 con QD+G (6 mg/kg/12 h); G3: 16 con QD+T (20 mg/kg/12 h); G4: 14 con QD+I (60 mg/kg/8 h); y G5: 16 con QD+L(20 mg/kg/12 h). Se valoró la respuesta terapéutica comparando la concentración de E. faecium en las vegetaciones cardiacas expresada comolog10 de las unidades formadoras de colonias por gramo de tejido (UFC/g). Se realizaron pruebas de cinética de letalidad bacteriana paralas asociaciones que mostraron mejor comportamiento in vivo: QD + I y QD + L. El patrón de sensibilidad de la cepa utilizada fue: sensiblepara L, intermedia para QD, resistente para T e I, y sin resistencia de alto grado para G. El tratamiento con QD logró una reducción significativa(p <0.001) en las UFC/g respecto al grupo control (9,49 frente a 7,31). No hubo diferencias significativas entre los grupos G1 (QDsola), G2 (QD + G) y G3 (QD + T), consiguiendo estos tres grupos una redución significativa respecto del grupo control (p <0.001). No hubodiferencias entre G4 (QD + I) y G5 (QD + L). Estos dos grupos se mostraron como los más eficaces en reducir la media de UFC/g en lasvegetaciones cardiacas (G4: 4,38 y G5: 4,04), con p <0.0001 respecto al grupo control y p <0.001 respecto a G1, G2 y G3. No se detectóningún cambio en la CMI de QD durante el tratamiento. Sólo la curva de letalidad correspondiente a la concentración de I de 32 mg/l (0,25x CMI) con QD 1 mg/l (0,25 x CMI) presentó una curva descendente a las 4 y 8 horas, sugiriendo una sinergia precoz que se perdió a las 8 horas.A la vista de estos resultados, la combinación de QD con I o L podría considerarse como alternativa terapéutica en la endocarditis porE. faecium multirresistente


The incidence of multidrug-resistant Enterococcus faecium is increasing despite advances in antibacterial therapy. Thus, new antibiotics arerequired to treat hospital- or community-acquired infections caused by these multidrug-resistant organisms. The aim of this study was tocompare the therapeutic efficacy of quinupristin-dalfopristin (QD) alone, or in combination with gentamicin (G), teicoplanin (T), imipenem(I) or levofloxacin (L) against a strain of multidrug-resistant E. faecium in an experimental model of aortic valve endocarditis in rabbits. Thestudy group consisted of 28 control animals. Eighty-two animals were treated with one of the following antibiotic regimens: G1: 18 animalsQD (30 mg/kg/8 h); G2: 18 animals QD+G (6 mg/kg/12 h); G3: 16 animals QD+T (20 mg/kg/12 h); G4: 14 animals QD+I (60 mg/kg/8 h);and G5: 16 animals QD+L (20 mg/kg/12 h). The response to therapy was determined by the comparison of the number of CFU/g of E. faeciumin each vegetation. In vitro, time-kill studies looking for synergy for the combinations that showed better efficacy in vivo were done.The sensitivity of the strain was intermediate to QD, resistant to T and I, and sensitive to L. There was no high-level resistance to G. QD alonerevealed a significant decrease (p <0.001) in the CFU/g in the control group (9.49 vs. 7.31). There were no differences in the average of CFU/gbetween the QD alone (G1), QD+G (G2) and QD+T (G3) groups. These three groups revealed a significant difference in decrease of CFU/grespect of the group control (p <0.001). There were no differences in the average of CFU/g between QD+I (G4) and QD+T (G5). These twogroups revealed the greatest decrease in average CFU/g (G4: 4.38 and G5: 4.04) with differences respect of the group control (p <0.0001)and respect of the groups G1, G2 and G3 (p <0.001). We did not detect any alteration of MIC from QD in the course of the treatment for eitherof the final isolations. Only the time kill corresponding to concentrations of I 32 mg/l (0.25 x MIC) and QD 1 mg/l (0.25 x MIC presents adescending slope in the curve at 4 and 8 h, suggesting an early synergy phenomenon, which was lost after 8 h. In light of these results, thecombination QD with I and L may be considered suitable alternatives for the treatment of multiresistant E. faecium


Assuntos
Animais , Feminino , Idoso , Coelhos , Humanos , Antibacterianos/uso terapêutico , Endocardite Bacteriana/tratamento farmacológico , Enterococcus faecium , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Teicoplanina/uso terapêutico , Virginiamicina/uso terapêutico , Modelos Animais de Doenças , Farmacorresistência Bacteriana Múltipla , Quimioterapia Combinada , Endocardite Bacteriana/microbiologia , Enterococcus faecium/isolamento & purificação , Gentamicinas/uso terapêutico , Infecções por Bactérias Gram-Positivas/microbiologia , Imipenem/uso terapêutico , Ofloxacino/uso terapêutico , Testes de Sensibilidade Microbiana
11.
Rev Clin Esp ; 204(9): 452-6, 2004 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-15388018

RESUMO

INTRODUCTION: P. aeruginosa causes serious infections with high mortality. OBJECTIVES: Identify the prognostic factors associated with higher mortality in P. aeruginosa bacteremias (PAB). METHODS: 211 consecutive cases of PAB were analyzed prospectively between 1992-1998. Blood cultures, isolation, and antimicrobial sensitivity were carried out according to microbiology standard methodology. The variables analyzed as prognostic factors were: sex, age, source of infection, background, main disease, initial clinical severity, foci, presence of complications, leukocyte count, type of antibiotic treatment and adaptation. Bivariate and multivariate statistical analyses were carried out by the method of logistic regression. RESULTS: Global mortality was 27.96%; factors associated with higher mortality in the bivariate study were main disease rapidly and eventually fatal, diabetes, a situation of critical initial clinical severity, lung focus, complications, neutropenia and inadequate antibiotic treatment. The logistic regression study, the critical initial clinical severity, and the presence of complications were the variables associated with worse prognosis. We did not find significant differences in the evolution among the patients who received monotherapy and those on combinations of antimicrobial drugs against pseudomonas. CONCLUSION: Higher mortality of PAB is statistically associated to the situation of critical initial clinical severity and to the presence of complications; therefore, an early diagnosis and adequate treatment to improve the morbidity and mortality are recommended.


Assuntos
Bacteriemia/mortalidade , Infecções por Pseudomonas/mortalidade , Pseudomonas aeruginosa/isolamento & purificação , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Quimioterapia Combinada/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/microbiologia , Fatores de Risco , Espanha/epidemiologia
12.
An Med Interna ; 21(4): 166-70, 2004 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-15109283

RESUMO

INTRODUCTION: The diagnostic of the pneumonia is the problems more important for its adequate treatment and best evolution. OBJECTIVES: To study in a prospective way the patron clinic de la NAC compared the documented with the not documented in a microbiological way. PATIENTS Y METHODS: We have studied patients with NAC hospitalized in the HUVA between January of 1991 and May of 1997. The diagnostical criterion of pneumonia and of the hospitable ingress were the classics accepted for this infections, was doing in all cases diagnostical studies not invasive. It was analyzed the clinical patron of the NAC microbiologically documented compare to with the not documented. In the same way, the documented was divided in typical and not typical according to the microorganisms aisled. Besides was realized an statistic study using tables of contingency and test Fisher. RESULTS: It was studied 409 patients with NAC, from which 161 (39.6%) had microbiological documentation, it was found 119 micro organism typical and 42 atypical. On the one hand, the female sex, EPOC, fever, tos and purulence esputum and hyperglucaemia, were associated significantly with the documented NAC. The presence of cardiopaty, seriously initial clinical situation, gastrointestinal disorders and previous infections and use of antibiotics, were associated with not documented. The age more than 65 years, presence of comorbility, purulence sputum, pleural pain, toghether with VSG>50 and lobar infiltrate, were associated significantly to typical pneumonia, while tabaquical habit and extrapulmonary sintoms (artromialgias) were with the atypical. CONCLUSIONS: The knowledge of the clinical patrons of the NAC are great impact in the diagnostic and treatment antibiotic adecuate.


Assuntos
Pneumonia Bacteriana/epidemiologia , Pneumonia Bacteriana/microbiologia , Idoso , Contagem de Colônia Microbiana , Infecções Comunitárias Adquiridas/diagnóstico , Infecções Comunitárias Adquiridas/epidemiologia , Infecções Comunitárias Adquiridas/microbiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia Bacteriana/diagnóstico , Estudos Prospectivos , Fatores de Risco
13.
An. med. interna (Madr., 1983) ; 21(4): 166-170, abr. 2004.
Artigo em Es | IBECS | ID: ibc-31252

RESUMO

Introducción: La dificultad en el diagnóstico clínico de la NAC es uno de los problemas más importantes para su adecuado tratamiento. Objetivos: Estudiar de forma prospectiva el patrón clínico de la NAC comparando las documentadas con las no documentadas microbiológicamente. Pacientes y métodos: Hemos estudiado 409 pacientes diagnosticados de NAC ingresados en el HUVA entre enero de 1991 y mayo de 1997.Los criterios diagnósticos de neumonía y de ingreso hospitalario fueron los clásicos aceptados para estas infecciones. Se analizaron el patrón clínico de las NAC documentadas microbiológicamente de forma comparativa con las no documentadas y las documentadas se dividieron en típicas y atípicas de acuerdo con los microorganismos aislados. Se realizó estudio estadístico mediante tablas de contingencia y test exacto de Fisher. Resultados: De todos ellos 409/161 (39,6 por ciento) tenían documentación microbiológica, encontrándose 119 microorganismos típicos y 42 atípicos. El sexo mujer, la presencia de EPOC, fiebre, expectoración purulenta e hiperglucemia se asociaron significativamente con las NAC documentadas. La presencia de cardiopatía, situación clínica inicial mala, alteraciones gastrointestinales y existencia de infecciones y uso previo de antibióticos, se asociaron significativamente con las no documentadas. La edad mayor de 65 años, presencia de comorbilidad, expectoración purulenta, dolor pleural junto con VSG>50 e infiltrado lobar lo encontramos asociado significativamente a las típicas, mientras que el hábito tabáquico y presencia de síntomas extrapulmonares (artromialgias) lo fueron con la atípicas. Conclusiones: El conocimiento de los patrones clínicos de la NAC es de gran impacto en el diagnóstico precoz y tratamiento antibiótico adecuado (AU)


Assuntos
Masculino , Pessoa de Meia-Idade , Feminino , Idoso , Humanos , Contagem de Colônia Microbiana , Estudos Prospectivos , Pneumonia Bacteriana , Fatores de Risco , Infecções Comunitárias Adquiridas
14.
Rev. esp. quimioter ; 16(3): 289-294, sept. 2003.
Artigo em Es | IBECS | ID: ibc-27508

RESUMO

La protocolización razonada y consensuada, mediante la diversificación del consumo de antibióticos, influye significativamente en su consumo, deteniendo y disminuyendo el desarrollo de resistencias bacterianas en los microorganismos gramnegativos aislados con más frecuencia en un hospital general. El aumento del consumo de piperacilina-tazobactam lo hemos encontrado asociado significativamente con un incremento de la resistencia en E. cloacae, siendo menor esta tendencia en K. pneumoniae y E. coli. Su actividad frente a P. aeruginosa no se ve afectada durante todo el estudio, manteniendo una alta sensibilidad al final, de forma semejante frente a P. mirabilis y con recuperación parcial de su actividad frente a A. baumannii. No encontramos diferencias estadísticamente significativas entre el consumo estable de cefotaxima, ciprofloxacino, ceftazidima e imipenem y las resistencias bacterianas en E. coli, P. aeruginosa, P. mirabilis, K. pneumoniae, E. cloacae y A. baumannii. Imipenem presenta mayor actividad frente a E. coli, K. pneumoniae, E. cloacae y A. baumannii. Piperacilina-tazobactam es más activo frente a P. aeruginosa. Ciprofloxacino muestra la menor actividad frente a E. coli y P. mirabilis. Cefotaxima presenta la menor actividad frente a E. cloacae, P. aeruginosa y A. baumannii. Ceftazidima tiene una actividad estable y semejante a la de piperacilinatazobactam frente a E. coli, P. mirabilis, K. pneumoniae, E. cloacae y A. baumannii (AU)


Assuntos
Humanos , Farmacorresistência Bacteriana , Consenso , Espanha , Estudos Prospectivos , Antibacterianos , Protocolos Clínicos , Uso de Medicamentos , Hospitais Gerais
15.
Rev Esp Quimioter ; 16(3): 289-94, 2003 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-14702120

RESUMO

Reasoned and consensual protocols, by means of diversification of the use of antibiotics, significantly influence their consumption, preventing and reducing the development of bacterial resistance against the Gram-negative microorganisms most frequently isolated in general hospitals. The increase in the consumption of piperacillin-tazobactam was found to be significantly associated with an increased resistance of E. cloacae, but less so in K. pneumoniae and E. coli. Its activity against P. aeruginosa and against P. mirabilis was not affected throughout the study and it maintained a high sensivity to the end against P. aeruginosa and against P. mirabilis and partial recovery of activity against A. baumannii. No statistically significant differences were found between the stable consumption of cefotaxime, ciprofloxacin, ceftazidime and imipenem and bacterial resistance against E. coli, P. aeruginosa, P. mirabilis, K. pneumoniae, E. cloacae and A. baumannii. Imipenem presented greater activity against E. coli, K. pneumoniae, E. cloacae and A. baumannii. Piperacillin-tazobactam showed greater activity against P. aeruginosa, while ciprofloxacin showed the least activity against E. coli and P. mirabilis. Cefotaxime had the least activity against E. cloacae, P. aeruginosa and A. baumannii. Ceftazidime showed stable activity and was similar to piperacillin-tazobactam against E. coli, P. mirabilis, K. pneumoniae, E. cloacae and A. baumannii.


Assuntos
Antibacterianos/uso terapêutico , Consenso , Farmacorresistência Bacteriana , Protocolos Clínicos , Uso de Medicamentos/normas , Uso de Medicamentos/estatística & dados numéricos , Hospitais Gerais , Humanos , Estudos Prospectivos , Espanha
16.
Rev. esp. quimioter ; 15(3): 233-240, sept. 2002.
Artigo em Es | IBECS | ID: ibc-18734

RESUMO

En los hospitales españoles se ha producido un aumento importante del consumo de antibióticos de amplio espectro. El objetivo de nuestro estudio fue valorar la influencia de la protocolización sobre el uso de estos antibióticos. Se realizó un estudio prospectivo y observacional a partir de la información que nos proporcionaba el Servicio de Farmacia acerca de las prescripciones de ceftriaxona, cefotaxima, ceftazidima, imipenem y ciprofloxacino en los Servicios de unidosis del hospital. El estudio estaba integrado por dos grupos: 1) grupo control (octubre-diciembre 1995), sin tener en cuenta los protocolos de tratamiento antibiótico, y 2) grupo de estudio durante los mismos meses del siguiente año (1996), teniendo en cuenta los protocolos consensuados. Los criterios sobre el tipo de paciente, infección, evolución y tratamiento antibiótico se valoraron de acuerdo con las normas de la literatura internacional para esta clase de estudios. Las características iniciales de los pacientes de ambos grupos eran similares. Tras la protocolización se observó una disminución en el consumo (108 casos en el grupo 2 frente a 207 casos en el grupo 1), un aumento en la adecuación (50,72 por ciento en el grupo 1 frente al 77,57 por ciento en el grupo 2), un aumento de la curación (78,26 por ciento en el grupo 1 frente al 91,67 por ciento en el grupo 2) y una disminución de las estancias en 5,01 días (22,99 días en el grupo 1 frente a 17,98 días en el grupo 2) con significación estadística, produciéndose un ahorro por paciente curado de 2073,74 euros. La protocolización consensuada y su adecuado cumplimiento constituyen un método de utilización de antibióticos de gran interés, ya que logran una mejora en la calidad de su uso y un mayor rendimiento. (AU)


Assuntos
Humanos , Estudos Prospectivos , Antibacterianos , Protocolos Clínicos , Uso de Medicamentos , Hospitais Gerais
20.
J Antimicrob Chemother ; 47(5): 623-9, 2001 May.
Artigo em Inglês | MEDLINE | ID: mdl-11328774

RESUMO

The efficacy of different antibiotics was compared in an experimental model of aortic valve endocarditis in rabbits, using a serotype 19 strain of Streptococcus pneumoniae resistant to penicillin (MIC 12 mg/L) and ceftriaxone (MIC 12 mg/L). The results were compared with those of a control group, which received no treatment. One hundred and nineteen animals were treated with one of the following antibiotic regimens: im procaine penicillin G at a dosage of 300,000 U/kg weight/12 h (16 animals); iv trovafloxacin, 13.3 mg/kg/12 h (31 animals); iv ceftriaxone, 75 mg/kg/24 h (21 animals); iv vancomycin, 20 mg/kg/12 h (15 animals) and im quinupristin-dalfopristin, 30 mg/kg/8 h (20 animals). All the antibiotics used in this study proved to be efficient in reducing numbers of S. pneumoniae and in increasing the percentage of aortic vegetations that were rendered sterile compared with the control group. Penicillin at the dosage used in our study was capable of achieving serum concentrations two or three times greater than the MIC, thus demonstrating its effectiveness as an antibiotic for this endocarditis model. No significant difference was observed between the effects of vancomycin, quinupristin-dalfopristin and penicillin. Vancomycin proved to be more efficient than trovofloxacin in reducing the bacterial load and increasing the numbers sterilized. There was also a tendency for this antibiotic to be more effective than ceftriaxone in reducing the bacterial load of the vegetations. There was a statistically significant correlation between the weight of the vegetations and their bacterial load. In the light of these results, vancomycin and quinupristin-dalfopristin may be considered suitable alternatives to penicillin for the treatment of penicillin-resistant S. pneumoniae endocarditis.


Assuntos
Endocardite Bacteriana/tratamento farmacológico , Fluoroquinolonas , Infecções Pneumocócicas/tratamento farmacológico , Animais , Anti-Infecciosos/uso terapêutico , Ceftriaxona/farmacologia , Ceftriaxona/uso terapêutico , Modelos Animais de Doenças , Resistência a Múltiplos Medicamentos , Endocardite Bacteriana/microbiologia , Humanos , Masculino , Naftiridinas/uso terapêutico , Resistência às Penicilinas , Penicilinas/uso terapêutico , Infecções Pneumocócicas/microbiologia , Coelhos , Streptococcus pneumoniae/efeitos dos fármacos , Streptococcus pneumoniae/isolamento & purificação , Vancomicina/uso terapêutico , Virginiamicina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...